To Your Health arrives in the City of Brotherly Love
WASHINGTON CVS/pharmacy is bringing its To Your Health community wellness program to the Philadelphia area starting June 19, the retailer has announced.
More than 80 events are planned at various CVS/pharmacy retail locations in Pennsylvania, Delaware and New Jersey through September. The community health screening events, also taking place this year in Atlanta and Washington, D.C., offer a $150 value in free health risk assessments and screenings to help improve access to preventive care to residents in urban and African-American communities.
The first To Your Health screening events in the Philadelphia area will be this weekend and will continue through the summer.
The To Your Health program, launched nationally in April in Atlanta, is part of efforts by CVS/pharmacy to improve access to preventive care in urban communities, including Philadelphia and Washington, D.C. In particular, CVS/pharmacy hopes to address critical health issues among African-Americans, who often have higher rates of diabetes and high blood pressure. For example, the rate of diabetes among African-Americans is 11.8%, versus 6.6% of non-Hispanic whites, according to the American Diabetes Association.
The To Your Health community wellness events provide diabetes, blood pressure, cholesterol and osteoporosis screenings, as well as examine patients for oral care and provide referrals for mammograms and pap smears. In addition, physicians are on hand to help patients interpret results and provide counsel on next steps.
In 2009, more than 195,000 people were screened at similar free community health screening events for the Hispanic community across the country, and serious health concerns were detected in an alarmingly high percentage of participants. Of the individuals screened:
- 33% had high cholesterol;
- 36% had a high-to-moderate risk of developing osteoporosis;
- 28% had hypertension; and
- 22% had diabetes, with more than half being diagnosed with diabetes for the first time.
Stater Bros. continues fundraising efforts for blood cancers
SAN BERNARDINO, Calif. Stater Bros. is partnering with The Leukemia & Lymphoma Society for three weeks in June to raise funds for leukemia, lymphoma and Hodgkin’s disease, the California-based grocer said Wednesday.
All 167 Stater Bros. locations will be participating in the fundraising campaign, which will offer customers the opportunity to purchase $1 paper balloons. The proceeds will benefit The Leukemia & Lymphoma Society. Last year, Stater Bros. raised more than $300,000 for the organization — 2010 marks the third year for the partnership.
“The Stater Bros. supermarket family is very happy to be able to give back because there are so many people who have been affected by blood cancers and it is imperative that we join in the fight to find a cure,” stated Jack Brown, chairman and CEO of Stater Bros. “We do not just do business in a community, we are part of each and every community we serve.”
Abbott, Neurocrine Biosciences to commercialize elagolix
ABBOTT PARK, Ill. Two drug makers will work together to develop a drug for the treatment of endometriosis, a condition estimated to affect 100 million women around the world.
Abbott and Neurocrine Biosciences said they would develop and commercialize the drug elagolix, which recently finished a mid-stage study as a treatment for endometriosis and also is under development as a treatment for uterine fibroids. Endometriosis causes chronic pelvic pain throughout the menstrual cycle and dysmenorrhea, pain associated with mestruation. Uterine fibroids are benign tumors that form on the wall of the uterus.
“Extensive preclinical and clinical experience with elagolix suggests this drug could be an important advance for women with endometriosis and uterine fibroids, highly prevalent conditions where there is a need for new treatments,” Abbott SVP pharmaceutical research and development John Leonard stated. “This agreement enhances Abbott’s late-stage pipeline, with the potential for additional compounds in earlier-stage development.”
Abbott will pay $75 million upfront to Neurocrine while funding ongoing development activities. Neurocrine also will be eligible to receive milestone payments of around $500 million and potential royalties.